Literature DB >> 28748450

Replicating Health Economic Models: Firm Foundations or a House of Cards?

Inigo Bermejo1, Paul Tappenden2, Ji-Hee Youn3.   

Abstract

Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is sometimes based on previous model-based analyses; this endeavour is usually referred to as model replication. Such model replication activity may involve the comprehensive reproduction of an existing model or 'borrowing' all or part of a previously developed model structure. Generally speaking, the replication of an existing model may require substantially less effort than developing a new de novo model by bypassing, or undertaking in only a perfunctory manner, certain aspects of model development such as the development of a complete conceptual model and/or comprehensive literature searching for model parameters. A further motivation for model replication may be to draw on the credibility or prestige of previous analyses that have been published and/or used to inform decision making. The acceptability and appropriateness of replicating models depends on the decision-making context: there exists a trade-off between the 'savings' afforded by model replication and the potential 'costs' associated with reduced model credibility due to the omission of certain stages of model development. This paper provides an overview of the different levels of, and motivations for, replicating health economic models, and discusses the advantages, disadvantages and caveats associated with this type of modelling activity. Irrespective of whether replicated models should be considered appropriate or not, complete replicability is generally accepted as a desirable property of health economic models, as reflected in critical appraisal checklists and good practice guidelines. To this end, the feasibility of comprehensive model replication is explored empirically across a small number of recent case studies. Recommendations are put forward for improving reporting standards to enhance comprehensive model replicability.

Mesh:

Year:  2017        PMID: 28748450     DOI: 10.1007/s40273-017-0553-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  29 in total

1.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Authors:  Stephen Palmer; Mark Sculpher; Zoe Philips; Mike Robinson; Laura Ginnelly; Ameet Bakhai; Keith Abrams; Nicola Cooper; Chris Packham; Khaled Alfakih; Alistair Hall; David Gray
Journal:  Int J Cardiol       Date:  2005-04-20       Impact factor: 4.164

2.  Cost-effectiveness of antidepressant treatment reassessed.

Authors:  S W Woods; J A Rizzo
Journal:  Br J Psychiatry       Date:  1997-03       Impact factor: 9.319

3.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

4.  Validation of the IMS CORE Diabetes Model.

Authors:  Phil McEwan; Volker Foos; James L Palmer; Mark Lamotte; Adam Lloyd; David Grant
Journal:  Value Health       Date:  2014-09       Impact factor: 5.725

5.  UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

Authors:  A J Hayes; J Leal; A M Gray; R R Holman; P M Clarke
Journal:  Diabetologia       Date:  2013-06-22       Impact factor: 10.122

6.  Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.

Authors:  Lars Oddershede; Simon Walker; Wolfgang Stöhr; David T Dunn; Alejandro Arenas-Pinto; Nicholas I Paton; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

7.  Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality.

Authors:  Sam Norton; Amanda Sacker; Josh Dixey; John Done; Peter Williams; Adam Young
Journal:  Rheumatology (Oxford)       Date:  2013-08-08       Impact factor: 7.580

8.  The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.

Authors:  Anthony J Batty; Ryan N Hansen; Lisa M Bloudek; Sepideh F Varon; Esther J Hayward; Becky W Pennington; Richard B Lipton; Sean D Sullivan
Journal:  J Med Econ       Date:  2013-05-22       Impact factor: 2.448

9.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.

Authors:  David M Eddy; William Hollingworth; J Jaime Caro; Joel Tsevat; Kathryn M McDonald; John B Wong
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

10.  The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity.

Authors:  Maria Alva; Alastair Gray; Borislava Mihaylova; Philip Clarke
Journal:  Health Econ       Date:  2013-07-11       Impact factor: 3.046

View more
  7 in total

1.  Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic.

Authors:  Anthony J Hatswell
Journal:  Pharmacoecon Open       Date:  2020-06

2.  Response to 'Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"'.

Authors:  Inigo Bermejo; Paul Tappenden; Ji-Hee Youn
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

Review 3.  Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics.

Authors:  Emma McManus; David Turner; Tracey Sach
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

4.  Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"

Authors:  Emma McManus; Tracey Sach
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

5.  Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.

Authors:  Bhavesh Lakhotia; Ronan Mahon; Florian S Gutzwiller; Andriy Danyliv; Ivan Nikolaev; Praveen Thokala
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-16

6.  Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic.

Authors:  Anthony J Hatswell
Journal:  Pharmacoecon Open       Date:  2020-04-10

7.  Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success.

Authors:  Björn Schwander; Mark Nuijten; Silvia Evers; Mickaël Hiligsmann
Journal:  Pharmacoeconomics       Date:  2021-03-10       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.